Ancylostomiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
[[Anti-helminthic]] [[therapies]] are recommended among [[patients]] with [[ancylostomiasis]]. | [[Anti-helminthic]] [[therapies]] are recommended among [[patients]] with [[ancylostomiasis]].<ref name="pmid27929101">{{cite journal| author=Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R | display-authors=etal| title=Hookworm infection. | journal=Nat Rev Dis Primers | year= 2016 | volume= 2 | issue= | pages= 16088 | pmid=27929101 | doi=10.1038/nrdp.2016.88 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27929101 }} </ref> | ||
For stable uncomplicated cases | For stable uncomplicated cases | ||
===Adult=== | ===Adult=== | ||
*Preferred regimen: Albendazole 400 mg PO single dose | |||
*Alternative regimen: Mebendazole 100 mg PO q12h for 3 days | |||
*Alternative regimen: Pyrantel Pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose) | |||
==References== | ==References== | ||
Revision as of 09:05, 19 August 2021
|
Ancylostomiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ancylostomiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Ancylostomiasis medical therapy |
|
Risk calculators and risk factors for Ancylostomiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Anti-helminthic therapies are recommended among patients with ancylostomiasis.[1]
For stable uncomplicated cases
Adult
- Preferred regimen: Albendazole 400 mg PO single dose
- Alternative regimen: Mebendazole 100 mg PO q12h for 3 days
- Alternative regimen: Pyrantel Pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose)
References
- ↑ Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R; et al. (2016). "Hookworm infection". Nat Rev Dis Primers. 2: 16088. doi:10.1038/nrdp.2016.88. PMID 27929101.